Victory Capital Management Inc Galapagos Nv Transaction History

Victory Capital Management Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 04, 2020	SELL	$146.12 - $215.82 $6.33 Million - $9.36 Million	-43,352 Closed	0 $0
Q3 2019 Nov 12, 2019	BUY	$130.44 - $187.64 $1.37 Million - $1.98 Million	10,526 Added 32.07%	43,352 $6.62 Million
Q2 2019 Aug 15, 2019	BUY	$111.45 - $128.93 $948,439 - $1.1 Million	8,510 Added 35.0%	32,826 $4.23 Million
Q1 2019 May 03, 2019	SELL	$89.61 - $117.78 $607,555 - $798,548	-6,780 Reduced 21.8%	24,316 $2.86 Million
Q4 2018 Feb 05, 2019	BUY	$87.81 - $110.65 $1.12 Million - $1.41 Million	12,730 Added 69.31%	31,096 $2.85 Million
Q3 2018 Nov 01, 2018	SELL	$90.63 - $120.22 $86,098 - $114,209	-950 Reduced 4.92%	18,366 $2.07 Million
Q2 2018 Aug 02, 2018	SELL	$88.4 - $105.34 $91,936 - $109,553	-1,040 Reduced 5.11%	19,316 $1.78 Million
Q1 2018 May 04, 2018	BUY	$94.51 - $120.23 $194,690 - $247,673	2,060 Added 11.26%	20,356 $2.03 Million
Q4 2017 Feb 01, 2018	BUY	$84.48 - $104.02 $1.55 Million - $1.9 Million	18,296	18,296 $1.72 Million

12.3M

69.1K

42.7K

Ticker GLPG
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,835,500
Market Cap $1.58B
Description
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative coliti...

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

Stay updated on Victory Capital Management Inc with notifications on news.